Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 2
2018 4
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
Argilés G, Mulet N, Valladares-Ayerbes M, Viéitez JM, Grávalos C, García-Alfonso P, Santos C, Tobeña M, García-Paredes B, Benavides M, Cano MT, Loupakis F, Rodríguez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and UNICANCER GI; The, REARRANGE investigators; Principal investigator; Argilés G, Tabernero J; Steering Committee; Investigators. Argilés G, et al. Among authors: tobena m. Eur J Cancer. 2022 Dec;177:154-163. doi: 10.1016/j.ejca.2022.09.037. Epub 2022 Oct 14. Eur J Cancer. 2022. PMID: 36335783 Free article. Clinical Trial.
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.
Grávalos C, Carrato A, Tobeña M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limón ML, Safont MJ, Martínez de Castro E, García-Alfonso P, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Grávalos C, et al. Among authors: tobena m. Clin Colorectal Cancer. 2018 Jun;17(2):e323-e329. doi: 10.1016/j.clcc.2018.02.004. Epub 2018 Feb 17. Clin Colorectal Cancer. 2018. PMID: 29551560 Clinical Trial.
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez D, Tobeña M, Fernández-Plana J, Sebio A, Virgili AC, Cirera L, Barnadas A, Riera P, Sullivan I, Salazar J. Páez D, et al. Among authors: tobena m. Br J Cancer. 2019 Jan;120(2):190-195. doi: 10.1038/s41416-018-0348-7. Epub 2018 Dec 26. Br J Cancer. 2019. PMID: 30585257 Free PMC article. Clinical Trial.
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M. Sebio A, et al. Among authors: tobena m. Pharmacogenet Genomics. 2013 Mar;23(3):142-7. doi: 10.1097/FPC.0b013e32835d9b0b. Pharmacogenet Genomics. 2013. PMID: 23324806